Weltnachrichten – AU – Creso up 50% in a week, more catalysts are imminent


. .

We track your page views and clicks so we can continue to improve the website for our users.

Shares in Creso Pharma Limited (ASX: CPH; FRA: 1X8) suffered a rift last week as the company unveiled a number of promising developments that will have a material impact on its bottom line.

The most recent of these occurred today when Creso Pharma announced to the market that three new orders (POs) totaling 277. 000 CHF (Swiss Francs – 414. 000 AUD) for its Anibidiol® line of animal health products.

With the new orders, the total orders generated by Creso Pharma’s animal health segment for 2020 will be increased to approx. 975. 000 AUD (634. 000 CHF), which underscores the strong demand for the company’s industry-leading products.

Current orders are expected to be shipped to commercial partners in Europe in the coming weeks, and the partners will then market the products more widely to consumers.

These orders are a significant achievement for Creso Pharma and underscore management’s ability to meet stringent regulatory requirements for commercializing hemp products across Europe and its ability to drive growth initiatives in challenging market conditions.

The demand for the products remains high and these additional orders are further confirmation of the success of the Anibidiol® product line in the fast growing European animal health market.

Importantly, management said initiatives to expand the product portfolio to increase the footprint in the animal health sector are ongoing.

Creso continues to review plans to expand its animal health portfolio with additional innovative products such as various hemp flour and hemp seed oil products.

As the demand for existing products grows, management is also developing strategies to improve its presence in the industry.

Given the recent regulatory changes, Creso Pharma sees rapid growth in the European Union and global markets and is extremely well positioned to benefit from it.

In this context, a recent development that Creso Pharma launched on Monday should be taken into account.

On 19. November 2020 the Court of Justice of the European Union (ECJ) ruled that the member states may not prohibit the marketing of lawfully produced CBD.

Furthermore, the ECJ ruled that CBD is not considered a narcotic and therefore CBD can be freely sold in the European Union (EU). .

This decision could bring significant benefits to Creso Pharma, especially given that the company already has trade agreements in the region.

Jorge Wernli, Commercial Director of Creso Pharma, discussed the group’s animal health business and the prospects for further expansion: “These orders are an important achievement for the company in this challenging regulatory environment and COVID era.

‘’ They underscore the demand we are seeing across Europe for our innovative products and confirm the company’s strategy of investing in the animal health business.

“We assume that the animal health segment will continue to grow. Further orders are expected in the coming months.

Management is also exploring a number of ways to further enter the market and we believe we are well positioned to take a number of initiatives to expand our presence in this space. ”

With this outlook in mind, as well as the upcoming regulatory changes in Australia that should require TGA approval for over-the-counter (OTC) sales of CBD products, it’s easy to identify a number of short-term stock price catalysts that could be the latest price momentum from Maintain Creso Pharma.

The next few investors have been investing in ASX small-cap stocks for years, with their best small-cap picks yielding $ 1. 200%, 1. Get 120%, 900% and 678%. .

S3 Consortium Pty Ltd (AUTO No.. 433913) is a Company Authorized Agent of LeMessurier Securities Pty Ltd (AFSL No.. 296877). The information contained in this article is for general information only. Any advice is just general advice. Neither your personal goals, your financial situation nor your needs were taken into account. Accordingly, you should consider how appropriate the advice (if any) is for these goals, financial situation and needs before responding to the advice.

S3 Consortium Pty Ltd does and seeks business with companies listed in its articles. Investors should therefore be aware that the company may have a conflict of interest that could affect the objectivity of this article. Investors should view this article as only one factor in making an investment decision. The editors of this article also want to disclose that they can hold this stock in their portfolios and that any decision to buy this stock should be made after the buyer has made their own inquiries about the validity of information in this article.

The information contained in this article is current as of the final date. The information contained in this article is based on sources believed by S3 Consortium Pty Ltd to be reliable and publicly available. The S3 consortium will never acquire, disclose or use “inside information”.

Finfeed was founded seven years ago. com is Australia’s leading and longest running investor and financial news, education and expert opinion website.

Finfeed was published by StocksDigital and was created to provide daily coverage of the rises and falls of stocks listed on the ASX in the small-cap market.

As the first digital publication dedicated specifically to this area, Finfeed soon became the most trusted publication on the market, quickly generating over two million page impressions – a number that continues to grow.

Finfeed. com offers its readers informative articles on the latest market-moving #ASX small cap news, as well as exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, business performance, start-ups and much more.

Finfeed. com is the only media organization operating under the strength of a financial services license and supported by leading journalists and analysts with their own brands.

The website aims to inform, educate and entertain content that deals with financial issues.

Finfeed is a leading source of investor and market information. Everything investors need to know about investing is written in a way that anyone can understand.

Over the years, the site has expanded beyond just small cap coverage to showcase Australia’s leading ASX-listed small, mid and large caps, as well as some of the country’s most successful CEOs and business leaders, and find out what they are makes ticking.

The information on this website is only general information. Any advice is just general advice. Your personal goals, your financial situation or your needs were not taken into account. Accordingly, you should consider how appropriate the counseling (if any) is for these goals, financial situation and needs before responding to the counseling. S3 Consortium Pty Ltd (AUTO No.. 433913) is a Company Authorized Agent of LeMessurier Securities Pty Ltd (AFSL No.. 296877).

Creso Pharma, ASX: CPH, product, pharmaceutical industry, FRA: 1X8

World news – AU – Creso rises by 50% in a week, further catalysts are imminent
Related title :
Creso in one Week up 50% More catalysts are imminent
Creso Pharma receives three new orders from Europe for its anibidiol line of animal health products
Creso Pharma takes up steam with more orders for hemp oil Pet products

Ref: https://finfeed.com


Donnez votre point de vue et aboonez-vous!


Votre point de vue compte, donnez votre avis

[maxbutton id= »1″]